Experimental drug helps repair DNA damage and reduce brain inflammation in Alzheimer’s-like mice
King's College London researchers say KCL-286, first developed for spinal cord injuries, has already cleared Phase 1 human safety trials, though its effect on Alzheimer's in people is not yet known
Scientists at King’s College London have identified an experimental drug that helped repair broken DNA and reduced brain inflammation in a mouse model of Alzheimer’s disease, and that has already completed Phase 1 human safety and tolerability trials in the course of its earlier development. The drug, KCL-286, targets several processes linked to the disease at once, unlike treatments that focus primarily on protein buildup. Its effectiveness against Alzheimer’s in humans has not been established, and the new findings remain preclinical.